跳至主要内容
临床试验/NCT04881682
NCT04881682
招募中
2 期

Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

University of Ulm2 个研究点 分布在 1 个国家目标入组 20 人2023年5月1日

概览

阶段
2 期
干预措施
Immunoadsorption
疾病 / 适应症
CIDP
发起方
University of Ulm
入组人数
20
试验地点
2
主要终点
Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score
状态
招募中
最后更新
昨天

概览

简要总结

This is a randomized controlled study evaluating safety and efficacy of repeated immunoadsorption versus immunoglobulins in steroid-refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

注册库
clinicaltrials.gov
开始日期
2023年5月1日
结束日期
2028年3月1日
最后更新
昨天
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

发起方
University of Ulm
责任方
Principal Investigator
主要研究者

Albert Christian Ludolph, Prof.

Prof. Dr.

University of Ulm

入排标准

入选标准

  • Diagnosis of possible, probable, or definite CIDP (typical or atypical) according to European Federation of Neurological Societies (EFNS) guidelines
  • Disease duration of 3 years or less
  • Age 18 years or above
  • Previous treatment with methyl-prednisolone and insufficient therapeutic response as judged by the treating physician, or contraindications against methyl-prednisolone, or clinically significant side effects under methyl-prednisolone therapy as judged by the treating physician

排除标准

  • Clinical or laboratory evidence of manifest systemic infection, i.e., C-reactive protein (CRP) above 20 mg/l, or evidence of nitrite-positive urinary tract infection
  • Intake of angiotensin converting enzyme inhibitor within 1 week before first treatment
  • immunoglobulin A deficiency
  • Other contraindications against immunoadsorption or intravenous immunoglobulins

研究组 & 干预措施

Immunoadsorption

3 cycles of immunoadsorption in week 1, 7, and 13 after randomization. One cycle consists of 5 sessions on 5 consecutive days with processing of the 2-fold plasma volume on the first day and the 2.5-fold plasma volume on consecutive days, using regenerative adsorbers (Therasorb, Miltenyi Biotec, Bergisch Gladbach)

干预措施: Immunoadsorption

Immunoglobulins

5 cycles of intravenous immunoglobulins in week 1, 4, 7, 10, and 13 after randomization. The first cycle consists of 5 intravenous applications of immunoglobulins on 5 consecutive days in a dosage of 0.4 g per kg body weight per day. Subsequent cycles consist of 2 intravenous applications of immunoglobulins on 2 consecutive days in a dosage of 0.5 g per kg body weight per day.

干预措施: Immunoglobulins

结局指标

主要结局

Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score

时间窗: 15 weeks

Standard clinical score for CIDP, quantifying disability.

CIDP Score

时间窗: 15 weeks

The CIDP Score is a combined score of Inflammatory Cause and Treatment (INCAT) Disability Score, Oxford Muscle Strength Score, and Vibration Score, with each subscore equally weighted.

Oxford Muscle Strength Score (Medical Research Council, MRC)

时间窗: 15 weeks

Standard clinical score for evaluation of muscle strength / paresis. Muscle strength is evaluated on a scale between 0/5 (no movement) and 5/5 (full strength) at 8 pre-defined muscles (one proximal and one distal muscle at each extremity).

Vibration Score

时间窗: 15 weeks

Standard clinical score for evaluation of pallesthesia, using a 256 Hz tuning fork. The individual perception threshold for vibration sensations on a scale between 0/8 (no perception) and 8/8 (normal perception) will be determined at 4 predefined spots (processus styloideus radii and malleolus lateralis on each side).

次要结局

  • Neurofilament Light Chain (NfL)(1, 7, 13, and 15 weeks)
  • Nerve Conduction Velocity(15 weeks)
  • Immunoglobulin A(1, 7, 13, and 15 weeks)
  • Interleukin-6(1, 7, 13, and 15 weeks)
  • Anti-neurofascin155(1, 7, 13, and 15 weeks)
  • Anti-contactin-associated-protein1(1, 7, 13, and 15 weeks)
  • CIDP Score(1, 7, and 13 weeks)
  • Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score(1, 7, and 13 weeks)
  • Pain(1, 7, 13, and 15 weeks)
  • Euro Quality of Life 5 Dimension 5 Levels (EQ-5D-5L)(1, 7, 13, and 15 weeks)
  • Interleukin-1(1, 7, 13, and 15 weeks)
  • Immunoglobulin M(1, 7, 13, and 15 weeks)
  • Anti-contactin-1(1, 7, 13, and 15 weeks)
  • Anti-neurofascin140(1, 7, 13, and 15 weeks)
  • Therapeutic Response(15 weeks)
  • Oxford Muscle Strength Score (Medical Research Council, MRC)(16 weeks)
  • N20 Latency(15 weeks)
  • P40 Latency(15 weeks)
  • Vibration Score(16 weeks)
  • Immunoglobulin G(1, 7, 13, and 15 weeks)
  • Anti-neurofascin186(1, 7, 13, and 15 weeks)

研究点 (2)

Loading locations...

相似试验